Vimarsana
Biggest News Aggregation in the World

Page 3 - Scientific Presentations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scientific Presentations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scientific Presentations Today - Breaking & Trending Today

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

SCYNEXIS reported the closing of an exclusive license agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets). SCYNEXIS received an upfront pay...

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update - SCYNEXIS (NASDAQ:SCYX) - Vimarsana News

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update - SCYNEXIS (NASDAQ:SCYX)

SCYNEXIS reported the closing of an exclusive license agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets). SCYNEXIS received an upfront payment of $90 million upon deal close.SCYNEXIS announced the

4DMT Presents Additional Positive Interim Data from - Vimarsana News

4DMT Presents Additional Positive Interim Data from

Dose response demonstrated in favor of highest tested dose of 3E10 vg/eye, including 100% reduction in supplemental anti-VEGF injections (4 of 4 evaluable...

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 - Aligos Therapeutics (NASDAQ:ALGS) - Vimarsana News

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 - Aligos Therapeutics (NASDAQ:ALGS)

-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks- -Data collectively

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 - Vimarsana News

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks- -Data collectively highlight company’s progress advanc...